Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer
- 31 March 2010
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 116 (3), 378-383
- https://doi.org/10.1016/j.ygyno.2009.10.087
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125Cancer Epidemiology, Biomarkers & Prevention, 2009
- Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian CancerCancer Epidemiology, Biomarkers & Prevention, 2008
- Combining a symptoms index with CA 125 to improve detection of ovarian cancerCancer, 2008
- Use of Yeast-SecretedIn vivoBiotinylated Recombinant Antibodies (Biobodies) in Bead-Based ELISAClinical Cancer Research, 2008
- Development of an ovarian cancer symptom indexCancer, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Bead-Based ELISA for Validation of Ovarian Cancer Early Detection MarkersClinical Cancer Research, 2006
- Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal DistributionsJournal of Clinical Oncology, 2004
- Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinomaGynecologic Oncology, 2004
- Frequency of Symptoms of Ovarian Cancer in Women Presenting to Primary Care ClinicsJAMA, 2004